Skip to main content
NewslettersWatchlist

Curis Inc(CRIS-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low10.35
Day High10.67
Open:10.54
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.
Select a category then submit the form to load news
PR Newswire
Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
PR Newswire
Curis to Present at Upcoming Healthcare Conferences in September
PR Newswire
Curis Provides Second Quarter 2023 Business Update
PR Newswire
Curis to Release Second Quarter 2023 Financial Results and Hold Conference Call on August 3, 2023
PR Newswire
FDA Removes Partial Clinical Hold on TakeAim Leukemia Study RP2D Established at 300 mg BID
PR Newswire
Curis Announces $15.1 Million Registered Direct Offering
PR Newswire
Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
PR Newswire
Curis Provides First Quarter 2023 Business Update
PR Newswire
Curis to Release First Quarter 2023 Financial Results and Hold Conference Call on May 4, 2023
PR Newswire
Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
PR Newswire
Curis Provides Fourth Quarter 2022 Business Update
PR Newswire
Curis Reschedules Fourth Quarter 2022 Business Update and Conference Call
PR Newswire
Curis to Release Fourth Quarter 2022 Financial Results and Hold Conference Call on March 9, 2023
PR Newswire
Curis Announces Additional Encouraging Clinical Data from TakeAim Leukemia Study of emavusertib (CA-4948) in Monotherapy R/R AML and hrMDS
PR Newswire
Curis to Host Webcast to Discuss Updated Emavusertib Clinical Data in Leukemia
PR Newswire
Curis Provides Third Quarter 2022 Business Update
PR Newswire
Curis Announces Three Presentations at SITC 2022
PR Newswire
Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
PR Newswire
Curis Announces Date for the 1st Symposium on IRAK4 in Cancer
PR Newswire
Curis Announces Date for the 2nd Annual VISTA Symposium
PR Newswire
FDA Lifts Partial Clinical Hold on the TakeAim Lymphoma Study of Emavusertib
Motley Fool
Curis (CRIS) Q2 2022 Earnings Call Transcript
PR Newswire
Curis Reports Second Quarter 2022 Financial Results and Business Update
PR Newswire
Curis Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
PR Newswire
Curis to Release Second Quarter 2022 Financial Results and Hold Conference Call on August 4, 2022
PR Newswire
Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Motley Fool
Curis (CRIS) Q1 2022 Earnings Call Transcript
Motley Fool
Curis (CRIS) Q4 2021 Earnings Call Transcript
Globe NewsWire
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Curis, Inc. - CRIS
Globe NewsWire
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Curis, Inc. - CRIS
Globe NewsWire
Curis, Inc. Investors: Company Investigated by the Portnoy Law Firm
Globe NewsWire
CytomX Therapeutics Appoints Dr. Mani Mohindru to Board of Directors

Profile

Curis, Inc. is a therapeutic drug development company focusing on cancer, neurological and dermatological disease indications, with technologies that utilize regulatory pathways that control repair and regeneration. Curis' product development involves the use of small molecules or proteins to modulate these pathways. The company has successfully used this technology and product development approach to produce several promising drug product candidates in the fields of cancer, neurological disorders, hair growth, kidney and other diseases, as well as cardiovascular disease.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2024.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2024 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.